266 Deformation imaging by strain in chronic heart failure over sacubitril–valsartan: a multicentre echocardiographic registry (discover)—ARNI

Autor: Giulia Elena Mandoli, Maria Concetta Pastore, Alberto Giannoni, Giovanni Benfari, Frank Lloyd Dini, Gianmarco Rosa, Nicola Riccardo Pugliese, Claudia Taddei, Michele Correale, Natale Daniele Brunetti, Pietro Mazzeo, Erberto Carluccio, Anna Mengoni, Andrea Igoren Guaricci, Laura Piscitelli, Rodolfo Citro, Michele Ciccarelli, Giuseppina Novo, Egle Corrado, Annalisa Pasquini, Valentina Loria, Giuseppe De Carli, Anna Degiovanni, Giuseppe Patti, Ciro Santoro, Luca Moderato, Mariantonietta Cicoira, Marco Canepa, Alessandro Malagoli, Michele Emdin, Matteo Cameli
Rok vydání: 2021
Předmět:
Zdroj: European Heart Journal Supplements. 23
ISSN: 1554-2815
1520-765X
Popis: Aims Sacubitril/valsartan have changed the treatment of heart failure with reduced ejection fraction (HFrEF), due to the positive effects morbidity and mortality partly mediated by left ventricular reverse remodelling (LVRR). The aim of this multicentre study was to identify echocardiographic predictors of LVRR after sacubitril/valsartan administration. Methods and results Patients with HFrEF requiring therapy with sacubitril/valsartan from 13 Italian centres were included. Echocardiographic indexes including speckle tracking echocardiography (STE) indexes were used to predict LVRR [defined as LV end-systolic volume reduction and ejection fraction (LVEF) improvement > 10% at follow-up] at 6 months follow-up as the primary endpoint. Changes in symptoms (NYHA class) and neurohormonal activations [N-terminal-pro-brain natriuretic peptide (NTproBNP)] were also evaluated as secondary endpoints. The final population (excluding patients with poor acoustic windows and missing data) consists of 341 patients [mean age: 65 ± 10 years; 18% female, median LVEF 30% (interquartile range: 25–34)]. At 6 months follow-up, 82 (24%) patients showed early complete response (LVRR and LVEF ≥35%), 55 (16%) early incomplete response (LVRR and LVEF Conclusions STE parameters at baseline could be useful to predict LVRR and clinical response to sacubitril-valsartan, and thus could be used as a guide for treatment in patients with HFrEF.
Databáze: OpenAIRE
Externí odkaz: